๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Standard medical treatment

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 10 trials in our China and India registers that name Standard medical treatment as an intervention. Synced 24 Sep 2026
10Trials tracked
9Recruiting now
7Lead sponsors
2Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Standard medical treatment is named as a drug or biological intervention in 10 clinical trials in our China and India trial registers, 9 of which are recruiting. Lead sponsors include Beijing Tiantan Hospital (4), Institute of Liver and Biliary Sciences, India (1) and Peking Union Medical College Hospital (1). Registered phases: Not applicable, Phase 3, Phase 2/3 and Observational. Conditions studied include Acute Ischemic Stroke; Stroke; Acute Liver Failure.

01

Clinical trials of Standard medical treatment

10 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06954155 Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND (ClinicalTrials.gov ↗)
Stroke
Phase 3 Recruiting Beijing Tiantan Hospital China
NCT07047014 Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke (ClinicalTrials.gov ↗)
Stroke, Ischemic, Medium Vessel Occlusions
Phase 3 Recruiting Beijing Tiantan Hospital China
NCT07606807 rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window (ClinicalTrials.gov ↗)
Acute Ischemic Stroke
Phase 3 Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University China
NCT07302854 Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion (ClinicalTrials.gov ↗)
Acute Ischemic Stroke, Medium Vessel Occlusion
Phase 2/3 Recruiting Xiang Luo China
NCT05322824 Clinical Registration Study of Patients With Intracranial / Carotid Stenosis (ClinicalTrials.gov ↗)
Cognitive Function, Stenosis
Observational Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine China
NCT04948749 Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial (ClinicalTrials.gov ↗)
ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent
Not applicable Recruiting Beijing Tiantan Hospital China
NCT06831643 Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure (ClinicalTrials.gov ↗)
Acute Liver Failure
Not applicable Recruiting Institute of Liver and Biliary Sciences, India India
NCT07094763 Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset (ClinicalTrials.gov ↗)
Acute Ischemic Stroke
Not applicable Recruiting The First Affiliated Hospital of University of Science and Technology of China China
NCT07377058 RCT of Tocilizumab for Anti-MDA5+DM (ClinicalTrials.gov ↗)
Dermatomyositis
Not applicable Recruiting Peking Union Medical College Hospital China
NCT07471256 Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (ClinicalTrials.gov ↗)
Intracerebral Hemorrhage Lobar
Phase 3 Not yet open Beijing Tiantan Hospital China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

13 conditions
Condition (as registered)Trials
Acute Ischemic Stroke3
Stroke2
Acute Liver Failure1
Dermatomyositis1
Stroke, Ischemic1
Medium Vessel Occlusions1
Intracerebral Hemorrhage Lobar1
Medium Vessel Occlusion1
ICAD - Intracranial Atherosclerotic Disease1
ICAS - Intracranial Atherosclerosis1
Drug-eluting Stent1
Cognitive Function1
Stenosis1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Beijing Tiantan Hospital4
Institute of Liver and Biliary Sciences, India1
Peking Union Medical College Hospital1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
Xiang Luo1
The First Affiliated Hospital of University of Science and Technology of China1
Second Affiliated Hospital, Zhejiang University, School of Medicine1
04

Trials by country register

RegisterStandard medical treatment trials
Clinical trials in China9
Clinical trials in India1

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Standard medical treatment works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Standard medical treatment (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.